Tuesday's Health Winners & Losers
TheStreet.com - USA
... ELN - commentary - Cramer's Take) shares sank Tuesday after a Piper Jaffray analyst said sales of the company's multiple sclerosis drug Tysabri could be lower ...

Analyst Worries About Tysabri
TheStreet.com - USA
Tysabri, the multiple sclerosis treatment from Elan (ELN - commentary - Cramer's Take) and Biogen Idec (BIIB - commentary - Cramer's Take), appears to be ...

---

fampridine acorda

Four-Bagger Biotech in One Day
MSNBC - USA
... This is the area where Acorda might run into problems, since the Fampridine phase III trial consisted of only 301 patients taking the drug or a placebo over a ...
See all stories on this topic

StreetInsider.com After-Hours Movers 09/26
StreetInsider.com (subscription) - Birmingham,MI,USA
... Acorda Therapeutics, Inc. ... today's 29% run-up and yesterday's 283% run-up after announcing positive results from its Phase 3 clinical trial of Fampridine-SR on ...
See all stories on this topic

---

B3 multiple sclerosis mice

Vitamin B3 may be useful against MS: animal study
Reuters - USA
... precursor, nicotinamide, a form of vitamin B3, has shown ... potential in a mouse model of multiple sclerosis (MS ... In mice with the MS-like disease EAE, nicotinamide ...

Vitamin B3 may benefit MS patients
Salt Lake Tribune - United States
A form of vitamin B3 may eventually help protect people with multiple sclerosis (MS) from ... Program at Children's Hospital Boston worked with mice that had ...

---